Diagnostic accuracy of urinary survivin mRNA expression detected by RT-PCR compared with urine cytology in the detection of bladder cancer: A meta-analysis of diagnostic test accuracy in head-to-head studies.
Diagnostic accuracy of urinary survivin mRNA expression detected by RT-PCR compared with urine cytology in the detection of bladder cancer: A meta-analysis of diagnostic test accuracy in head-to-head studies. Oncol Lett. 2020 Feb;19(2):1165-1174 Authors: Fu L, Zhang J, Li L, Yang Y, Yuan Y Abstract Survivin is a promising marker for the diagnosis of bladder cancer. The accuracy and clinical value of urinary survivin mRNA expression were compared with urine cytology, which is the standard diagnostic method for bladder cancer. Scientific databases, including PubMed, Web of Science, Cochrane Library and China National Knowledge Infrastructure, were searched in order to find studies that examined urinary survivin mRNA expression and urine cytology in the diagnosis of bladder cancer. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool in Revman 5.3 and data analysis was conducted using Stata/MP. The I2 statistic was used to evaluate heterogeneity and Deeks' funnel plot was generated to assess the possibility of publication bias. A total of 15 studies that evaluated a total of 1,624 patients were included in the present meta-analysis. The pooled sensitivity and specificity values for the detection of urinary survivin mRNA expression in the diagnosis of bladder cancer were 0.86 [95% confidence interval (CI), 0.81-0.90] and 0.95 (95% CI, 0.93-0.96), respectively. Regarding urine cytology, the pooled sensitivity and ...
Conclusion: These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment for NMIBC and MIBC. PMID: 32093463 [PubMed - in process]
Publication date: Available online 26 February 2020Source: Practical Radiation OncologyAuthor(s): Kimberly R. Gergelis, Cole R. Kreofsky, Christopher S. Choo, Jason Viehman, W Scott Harmsen, Scott C. Lester, Thomas M. Pisansky, Brian J. Davis, Bradley J. Stish, Richard Choo
Publication date: Available online 26 February 2020Source: Urology Case ReportsAuthor(s): Manabu Takai, Daiki Kato, Koji Iinuma, Yuka Muramatsu Maekawa, Keita Nakane, Tomohiro Tsuchiya, Shigeaki Yokoi, Takuya Koie
CONCLUSIONS: We discovered a vital regulatory mechanism of hsa_circ_0017247 in BLCA which might serve as a new therapeutic intervention for BLCA patients. PMID: 32096177 [PubMed - in process]
This study provides the first evidence of the urinary TERT promoter mutations to be used as simple and cost-effective non-invasive biomarkers for the early detection of bladder cancer.
Ganesh Nagarajan, Kaushal KundaliaIndian Journal of Cancer 2020 57(1):2-3
Conclusion: All cholecystectomy specimens must be examined by histopathologists who must decide whether processing for microscopy is needed. Microscopic examination may be reserved for the specimen with a macroscopic lesion. This will result in a reduction of costs and pathology workload without compromising patient management.
Urinary incontinence is a common presentation and can manifest either as stress, urge or mixed incontinence. Though primarily a condition affecting women, the increasing uptake of prostate surgery for benign disease and cancer, whereupon up to one in five patients end up experiencing stress incontinence, means the prevalence of incontinence in men is increasing. A thorough assessment is necessary to identify the underlying urological abnormality and to guide appropriate management. Conservative approaches consist of treating constipation, the use of containment devices, weight loss, bladder training and pelvic floor muscle training.
Date: Friday, 03 06, 2020; Speaker: Christopher Buck, Ph.D., Head, Tumor Virus Molecular Biology Section, National Cancer Institute, CCR; Building: Building 10 (Clinical Center); Lipsett Amphitheater; CME Credit; Videocast Event
Conditions: Bladder Cancer; Radiation Therapy Complication; Quality of Life Intervention: Drug: Degarelix Sponsor: Aarhus University Hospital Recruiting